AstraZeneca’s BAXFENDY™ (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with other antihypertensive ...
When you think of high blood pressure, lifestyle choices around nutrition or exercise may come to mind—not your hormones. But ...
US FDA approves AstraZeneca’s Baxfendy, an aldosterone synthase inhibitor to treat adults with hypertension: Cambridge, UK Wednesday, May 20, 2026, 10:00 Hrs [IST] AstraZenecas ...
Higher serum aldosterone levels among patients with chronic kidney disease (CKD) are independently associated with an increased risk for CKD progression and end-stage kidney disease (ESKD) regardless ...
Oral presentation highlights efficacy and safety profile of lorundrostat in patients with uncontrolled hypertension and chronic kidney disease ...
A drug that has been used to slow progression of kidney and cardiovascular disease in people with type 2 diabetes may also help people with chronic kidney disease who do not have diabetes, according ...
Please provide your email address to receive an email when new articles are posted on . Aldosterone is associated with an increased risk of chronic kidney disease progression and the development of ...
Increased levels of aldosterone are independently associated with a greater risk of type 2 diabetes, with the effects particularly notable in certain ethnic groups including African Americans and ...
EVEN when the diagnosis of primary aldosteronism is obvious before operation, there is no way to localize the adenoma. Preoperative demonstration of the tumor radiographically, as by retroperitoneal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results